Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform NaV1.7

This is the authors' abstract. We don't add key points for this paper.

Voltage-gated sodium ion channel subtype 1.7 (Na V 1.7) is a high interest target for the discovery of non-opioid analgesics. Compelling evidence from human genetic data, particularly the finding that persons lacking functional Na V 1.7 are insensitive to pain, has spurred considerable effort to develop selective inhibitors of this Na + ion channel target as analgesic medicines. Recent clinical setbacks and disappointing performance of preclinical compounds in animal pain models, however, have led to skepticism around the potential of selective Na V 1.7 inhibitors as human therapeutics. In this Perspective, we discuss the attributes and limitations of recently disclosed investigational drugs targeting Na V 1.7 and review evidence that, by better understanding the requirements for selectivity and target engagement, the opportunity to deliver effective analgesic medicines targeting Na V 1.7 endures.

This perspective highlights that despite recent setbacks, NaV1.7 remains a viable target for non-opioid analgesics if selectivity and target engagement are optimized.